Kenvue (NYSE:KVUE) Price Target Cut to $23.00 by Analysts at Evercore ISI

Kenvue (NYSE:KVUE) had its price objective dropped by stock analysts at Evercore ISI from $25.00 to $23.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “in-line” rating on the stock. Evercore ISI’s price objective indicates a potential upside of 23.42% from the company’s current price.

A number of other equities analysts also recently weighed in on KVUE. Royal Bank Of Canada reduced their price target on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. reduced their price target on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. Zacks Research raised Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Canaccord Genuity Group reduced their price target on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, Citigroup cut their price objective on Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a report on Tuesday, July 15th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.21.

Kenvue Price Performance

NYSE KVUE opened at $18.64 on Monday. The business has a 50 day simple moving average of $21.37 and a 200 day simple moving average of $22.38. Kenvue has a 52-week low of $17.15 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The stock has a market cap of $35.76 billion, a price-to-earnings ratio of 25.18, a PEG ratio of 2.67 and a beta of 0.83.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the prior year, the firm posted $0.32 EPS. The business’s revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kenvue

Several hedge funds have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. increased its position in Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after buying an additional 4,034 shares during the period. IFP Advisors Inc increased its position in Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after buying an additional 3,081 shares during the period. Starboard Value LP bought a new position in shares of Kenvue in the fourth quarter worth $467,864,000. Kingswood Wealth Advisors LLC bought a new position in shares of Kenvue in the first quarter worth $413,000. Finally, FORA Capital LLC bought a new position in shares of Kenvue in the first quarter worth $981,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.